Tumor Recurrence in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: Portal Hypertension as an Indicator of Recurrence of Hepatocellular Carcinoma
10.3348/jksr.2018.79.5.264
- Author:
Seong Won JANG
1
;
Yun Ku CHO
;
Ju Won KIM
;
Je Ryung GIL
;
Mi Young KIM
;
Young LEE
Author Information
1. Department of Radiology, Veterans Health Service Medical Center, Seoul, Korea. yunkucho2004@yahoo.co.kr
- Publication Type:Original Article
- From:Journal of the Korean Radiological Society
2018;79(5):264-270
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE:To evaluate the effect of portal hypertension on the tumor recurrence in patients with hepatocellular carcinoma (HCC) and without hepatic decompression following radiofrequency ablation (RFA).
MATERIALS AND METHODS:Treatment-naïve HCC patients within the Milan criteria and with Child-Pugh class A were included in this study, who had performed RFA in our hospital between January 2010 and March 2017. Univariate and multivariate analyses using the Cox proportional hazard model were performed to find the predictors of local or distant tumor recurrence.
RESULTS:Overall, 178 patients were included in this study. Median follow-up period was 40.2 months. The difference in the local tumor progression rates depending on the absence or presence of portal hypertension was not statistically significant (p = 0.195). The 1-, 3-, and 5-year distant intrahepatic tumor spread rates were 6.6%, 29.5%, and 537% in patients without portal hypertension, and 23.4%, 51.9%, and 63.6% in patients with portal hypertension, respectively. The difference was statistically significant (p = 0.011). Univariate and multivariate analysis showed that portal hypertension was an independent predictor for distant intrahepatic tumor spread (p = 0.008).
CONCLUSION:For HCC patients with Child-Pugh class A, portal hypertension adversely affected distant intrahepatic tumor progression.
